The Taxonomy of Subjective Cognitive Decline: Proposal and First Clinical Evidence from the Geneva Memory Clinic Cohort
- 22 May 2024
- journal article
- research article
- Published by S. Karger AG in Neurodegenerative Diseases
- Vol. 24 (1) , 16-25
Abstract
Introduction: Subjective cognitive decline (SCD) is characterized by subjective cognitive concerns without objective cognitive impairment and is considered a risk factor for cognitive decline and dementia. However, most SCD patients will not develop neurodegenerative disorders, yet they may suffer from minor psychiatric, neurological, or somatic comorbidities. The aim of the present study was to provide a taxonomy of the heterogeneous SCD entity and to conduct a preliminary validation using data from a memory clinic sample. Methods: Participants were fifty-five SCD individuals consecutively recruited at the Geneva Memory Center. Based on clinical reports, they were classified into three clinically pre-defined subgroups: (i) those with psychological or psychiatric comorbidities (Psy), (ii) those with somatic comorbidities (SomCom), (iii) and those with no apparent cause (NAC). Baseline demographics, clinical, cognitive, and biomarker differences among the SCD subgroups were assessed. Longitudinal cognitive changes (average 3 years follow-up) were modeled using a linear mixed model. Results: Out of the 55 SCD cases, 16 were SomCom, 18 Psy, and 21 NAC. 47% were female, mean age was 71 years. We observed higher frequency of APOE ε4 carriers in NAC (53%) compared to SomCom (14%) and Psy (0%, p = 0.023) and lower level of plasma Aβ42 in NAC (6.8 ± 1.0) compared to SomCom (8.4 ± 1.1; p = 0.031). SomCom subjects were older (74 years) than Psy (67 years, p = 0.011), and had greater medial temporal lobe atrophy (1.0 ± 1.0) than Psy (0.2 ± 0.6) and NAC (0.4 ± 0.5, p = 0.005). SomCom has worse episodic memory performances (14.5 ± 3.5) than Psy (15.8 ± 0.4) and NAC (15.8 ± 0.7, p = 0.032). We observed a slightly steeper, yet not statistically significant, cognitive decline in NAC (β = −0.48) compared to Psy (β = −0.28) and SomCom (β = −0.24). Conclusions: NAC features a higher proportion of APOE ε4 carriers, lower plasma Aβ42 and a trend towards steeper cognitive decline than SomCom and Psy. Taken together, these findings suggest that NACs are at higher risk of cognitive decline due to AD. The proposed clinical taxonomy might be implemented in clinical practice to identify SCD at higher risk. However, such taxonomy should be tested on an independent cohort with a larger sample size.Keywords
All Related Versions
This publication has 37 references indexed in Scilit:
- Dementia prevention in memory clinics: recommendations from the European task force for brain health servicesThe Lancet Regional Health - Europe, 2023
- Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementiaAlzheimer's & Dementia, 2018
- Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid BurdenJAMA Neurology, 2017
- AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measureNeuroImage, 2017
- Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older AdultsThe American Journal of Geriatric Psychiatry, 2015
- A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's diseaseAlzheimer's & Dementia, 2014
- Plasma Amyloid-β as a Predictor of Dementia and Cognitive DeclineArchives of Neurology, 2012
- Volume reduction of the entorhinal cortex in subjective memory impairmentNeurobiology of Aging, 2006
- Effects of age on volumes of cortex, white matter and subcortical structuresNeurobiology of Aging, 2005
- Memory complaints in patients with normal cognition are associated with smaller hippocampal volumesJournal of Neurology, 2004